2021
Immunophenotyping assessment in a COVID-19 cohort (IMPACC): A prospective longitudinal study
, , Rouphael N, Maecker H, Montgomery R, Diray-Arce J, Kleinstein S, Altman M, Bosinger S, Eckalbar W, Guan L, Hough C, Krammer F, Langelier C, Levy O, McEnaney K, Peters B, Rahman A, Rajan J, Sigelman S, Steen H, van Bakel H, Ward A, Wilson M, Woodruff P, Zamecnik C, Augustine A, Ozonoff A, Reed E, Becker P, Higuita N, Altman M, Atkinson M, Baden L, Becker P, Bime C, Brakenridge S, Calfee C, Cairns C, Corry D, Davis M, Augustine A, Ehrlich L, Haddad E, Erle D, Fernandez-Sesma A, Hafler D, Hough C, Kheradmand F, Kleinstein S, Kraft M, Levy O, McComsey G, Melamed E, Messer W, Metcalf J, Montgomery R, Nadeau K, Ozonoff A, Peters B, Pulendran B, Reed E, Rouphael N, Sarwal M, Schaenman J, Sekaly R, Shaw A, Simon V. Immunophenotyping assessment in a COVID-19 cohort (IMPACC): A prospective longitudinal study. Science Immunology 2021, 6: eabf3733. PMID: 34376480, PMCID: PMC8713959, DOI: 10.1126/sciimmunol.abf3733.Peer-Reviewed Original ResearchConceptsCOVID-19 cohortProspective longitudinal studyHost immune responseLongitudinal studyCOVID-19Identification of biomarkersHospitalized patientsRespiratory secretionsClinical criteriaDisease progressionImmune responseRadiographic dataImmunologic assaysEffective therapeuticsOptimal timingStudy designBiologic samplingSuch interventionsCohortSeveritySample collectionAssay protocolsPatients
2019
Multi‐site reproducibility of a human immunophenotyping assay in whole blood and peripheral blood mononuclear cells preparations using CyTOF technology coupled with Maxpar Pathsetter, an automated data analysis system
Bagwell CB, Hunsberger B, Hill B, Herbert D, Bray C, Selvanantham T, Li S, Villasboas JC, Pavelko K, Strausbauch M, Rahman A, Kelly G, Asgharzadeh S, Gomez‐Cabrero A, Behbehani G, Chang H, Lyberger J, Montgomery R, Zhao Y, Inokuma M, Goldberger O, Stelzer G. Multi‐site reproducibility of a human immunophenotyping assay in whole blood and peripheral blood mononuclear cells preparations using CyTOF technology coupled with Maxpar Pathsetter, an automated data analysis system. Cytometry Part B Clinical Cytometry 2019, 98: 146-160. PMID: 31758746, PMCID: PMC7543682, DOI: 10.1002/cyto.b.21858.Peer-Reviewed Original ResearchConceptsPeripheral blood mononuclear cellsWhole bloodPeripheral blood mononuclear cell preparationsDeep immune phenotypingBlood mononuclear cellsImmune cell populationsMononuclear cell preparationsCell populationsTranslational clinical researchWhole blood preparationsImmune phenotypingMononuclear cellsPBMC samplesClinical trialsImmune cellsClinical researchCyTOF technologyBlood preparationsInter-site reproducibilityBloodCell preparationsSingle donorMulti-site reproducibilityCellsProfiling assays
2015
Risk factors for West Nile virus infection and disease in populations and individuals
Montgomery RR, Murray KO. Risk factors for West Nile virus infection and disease in populations and individuals. Expert Review Of Anti-infective Therapy 2015, 13: 317-325. PMID: 25637260, PMCID: PMC4939899, DOI: 10.1586/14787210.2015.1007043.Peer-Reviewed Original ResearchConceptsWest Nile virusWest Nile virus infectionComplex immune interactionsRisk factorsAdvanced ageVirus infectionImmune responseSevere diseaseImmune interactionsClinical casesMosquito-borneCDC reportNile virusNaïve bird populationsInfectionDiseasePositive-strand RNA virusesRNA virusesVirusNew York CityHypertensionImmunosuppressionPopulationYork City
2014
Immune Markers Associated with Host Susceptibility to Infection with West Nile Virus
Qian F, Thakar J, Yuan X, Nolan M, Murray KO, Lee WT, Wong SJ, Meng H, Fikrig E, Kleinstein SH, Montgomery RR. Immune Markers Associated with Host Susceptibility to Infection with West Nile Virus. Viral Immunology 2014, 27: 39-47. PMID: 24605787, PMCID: PMC3949440, DOI: 10.1089/vim.2013.0074.Peer-Reviewed Original ResearchConceptsWest Nile virusSevere infectionsImmune markersIL-4IL-4 levelsSerum cytokine levelsSerum IL-4Nile virusSignificant risk factorsImmune system statusPeripheral blood cellsSevere neurological diseaseCytokine levelsAntibody levelsImmune statusRisk factorsHealthy subjectsStratified cohortWNV infectionNeurological diseasesInfectionAltered expression levelsBlood cellsAltered gene expression patternsHost susceptibility